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Spontaneous pneumomediastinum, pneumothorax and 
subcutaneous emphysema in COVID-19: case report and 
literature review
Shi Shan 1*, Li Guangming2*, Lei Wei3, Yang Xuedong1
ABSTRACT
Coronavirus Disease 2019 (COVID-19) has rapidly spread worldwide. Numerous 
studies have shown its typical and atypical CT findings. We report one COVID-19 patient 
who presented with a transient pneumothorax, spontaneous pneumomediastinum (SP), as 
well as subcutaneous emphysema during hospitalization. Chest CT andclinical findings were 
discussed, and a literature review is presented. The probable cause of SP in COVID-19 was 
alveolar damage. Once pneumothorax and SP were present, the patient should be carefully 
monitored to prevent respiratory deterioration, especially when lung lesions are severe.
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INTRODUCTION
Since the outbreak of Coronavirus Disease 2019 (COVID-19), it has quickly 
spread worldwide. Globally, people infected were more than 8.5 million and deaths 
are over 0.4 million on June 19th, according to the Johns Hopkins University’s 
COVID-19 map.
The common CT manifestations of COVID-19 include pure ground-glass 
opacities (GGO), GGO with reticular opacities, GGO with consolidation, as 
well as consolidations. Bilateral lung involvement is frequent, especially in the 
posterior parts and peripheral areas. Pleural effusion, pericardial effusion and 
lymphadenopathy are rarely seen1-3. Spontaneous pneumomediastinum (SP) 
and pneumothorax are extremely rare in COVID-19, up to now a total of eight 
cases have been reported in the literature4-11. We have also found one COVID-19 
patient who showed SP, pneumothorax, as well as subcutaneous emphysema 
during treatment. 
CASE REPORT
A 67-year-old man who worked in Wuhan, Hubei Province, China, returned to 
Xiangyang city from Wuhan on January 19th, 2020. Fever occurred since that day, and 
the highest temperature was 38.5 °C. The patient showed occasional cough, shortness 
of breathe after activity, without expectoration, obvious dyspneaand diarrhea. He 
had a 5-year history of hypertension and no other underlying diseases. On February 
7th 2020, a real-time reverse transcription-polymerase chain reaction (RT-PCR) for 
the COVID-19 was positive. Laboratory tests carried out on February 7th showed 
that SpO2, blood oxygen saturation, lymphocyte ratio and lymphocyte count were 
decreased; on the contrary, C-reactive protein, Erythrocyte sedimentation rate, 
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neutrophil count, neutrophil ratio and LDH were elevated; 
the liver test was also abnormal, and the tests results are 
shown in Table 1.
Chest CT was performed on January 28th 2020 
(Figure 1), on February 5th (Figure 2), on February 11th 
(Figure 3) and on March 3rd (Figure 4), respectively. 
Typical CT manifestations were found in the initial 
images, which included bilateral GGO with reticular 
opacities predominantly located in the periphery on 
January 28th; bilateral lung lesions progressed on February 
Table 1 - Laboratory test results on February 7th and 14th 2020.
Test Value (local reference range) February 7th Value on February 14th 
SpO2 93% (95-99%) 96%
blood oxygen saturation 88% (98%) -
lymphocyte ratio 7.1% (20-40%) 8.9%
lymphocyte count 0.58×10^9/L (1.1-3.2×10^9) 1.10×10^9/L
neutrophil ratio 89.5% (40-75%) 86.1%
neutrophil count 7.30×10^9/L (1.8-6.3×10^9/L) 10.69×10^9/L
C-reactive protein 110.00 mg/L (0.8-8 mg/L) -
Erythrocyte sedimentation rate 40 mm/h (0-15 mm/h) -
LDH 384 U/L (110-240 U/L) 257 U/L
ALT 106 U/L (30 U/L) 26 U/L
AST 28 U/L (29-35 U/L) 25 U/L
Figure 1 - Chest CT (performed with a Philips Ingenuity 128 CT Scanner, 5 mm slice thickness reconstruction) showing multiple 
GGO (short arrow) mainly on the periphery of both lungs, some lesions with reticular opacities.
Figure 2 - GGO (short arrow) range was larger than before, with diffuse distribution in both lungs, some lesions with reticular opacities.
Figure 3 - CT demonstrated GGO with consolidation in both lungs, some lesions with reticular opacities, the range slightly smaller 
than before. Distortion of lung structures was noted. Subcutaneous emphysema within the right upper chest wall (black triangle) 
and neck (not shown), SP (long arrow), as well as a small pneumothorax in the right chest (short arrow) appeared.
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5th; subcutaneous emphysema in the upper right part of the 
chest and neck, SP, and pneumothorax in the right chest 
occurred on February 11th (the last laboratory examination 
since the occurrence of mediastinal emphysema was 
on February 14th and the laboratory test results are 
shown in Table 1). The pulmonary lesions were treated 
conservatively and by March 3rd the CT images had totally 
regressed. 
Clinical treatment mainly included an antibiotic 
(Ceftazidime), an anti-viral (Arbidol), low-dose 
methylprednisolone intravenous drip therapy (1mg/kg), 
and symptomatic supportive therapy adjusted according to 
the clinical conditions. Low-flow nasal catheter at 3L/min 
of oxygen was used. No invasive ventilation was performed 
during the period of hospitalization. The patient was tested 
by RT-PCR for COVID-19 on March 4th and March 5th 
2020 and both tests were negative. Informed consent was 
obtained from the patient.
DISCUSSION
SP refers to a pneumomediastinum occurring in 
circumstances other than traumatic or of iatrogenic origin12. 
This patient did not undergo any invasive ventilation or 
surgical procedures during hospitalization, so that the 
pneumomediastinum was spontaneous.
In a previous study, SP developed in 11.6% of SARS 
patients and appeared 19.6±4.6 days after the onset of 
symptoms13. The SP in the COVID-19 patient reported 
here was diagnosed 23 days after the onset of symptoms, 
which was similar to those in SARS patients. The 
pulmonary pathology of COVID-19 greatly resembles 
the one seen in SARS, showing diffuse alveolar damage, 
cellular fibromyositis exudates, evident desquamation 
of pneumocytes and hyaline membrane formation14. 
We believe that the possible causes of SP in COVID-19 
were similar to those in SARS. The alveolar rupture 
as a consequence of severe diffuse alveolar damage13 
and episodes of coughing or Valsalva maneuver that 
increase the pressure in the chest as inducing factors, 
then causing interstitial emphysema, and air dissection 
along the bronchovascular sheaths into the mediastinum 
(SP)15. This can also help to explain why pneumothorax 
and subcutaneous emphysema occur simultaneously. 
In this case, pneumothorax and SP occurred after the 
progression of lung lesions (February 5th), suggesting that 
the occurrence of emphysema may be related to alveolar 
damage.
SP is generally a benign disease that may not need 
specific treatment and can be absorbed spontaneously. 
In the case reported here the SP was self-limited. SP, 
pneumothorax and subcutaneous emphysema were 
completely absorbed 21 days later. In SARS, high LDH 
level was associated with SP, and the development of SP 
was also associated with poor prognosis13. In this case, 
the maximum LDH was 384 U/L, considerably lower 
than the LDH levels in SP of SARS (LDH of 863 U/L)13. 
In the reported case, SP completely absorbed, and the 
patient’s conditions improved and stabilized. Therefore, 
the relationship between SP and LDH elevation, and also 
with prognosis has yet to be further studied.
Recent literature has reported eight cases of SP and 
pneumothorax in COVID-19, M: F=5 : 3, the average age 
was 44.0±19.7 years, one of the patients eventually died and 
the other seven patients finally recovered after conservative 
treatment, needle decompression or catheter chest drainage. 
The patient who died had extremely severe lung lesions 
that progressed rapidly8 (Table 2). Therefore, the prognosis 
of SP and pneumothorax may be related to the severity of 
pulmonary lesions, but there is no clear correlation with the 
magnitude of pneumothorax and SP. As pneumothorax and 
SP are found, the patient should be carefully monitored to 
prevent respiratory deterioration, especially when the lung 
lesions are severe. 
CONCLUSIONS
SP, pneumothorax and subcutaneous emphysema are 
extremely rare in COVID-19. The probable cause of SP in 
COVID-19 in the reported case was alveolar damage. SP 
and pneumothorax may be related to death when SP and 
pneumothorax are found, and the patient should be carefully 
monitored to prevent respiratory deterioration.
Figure 4 - Follow-up CT showing that the density of the original lesion was reduced; but new GGO was found (Figure 4D, short 
arrow). Subcutaneous emphysema, SP and pneumothorax had been completely absorbed. 
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